Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells

Hepatology

Volumn 53, Issue 1, 2011, Pages 148-159

  Chen, Mei Chuan ^a,b   Chen, Chun Han ^a,b   Chuang, Hsiao Ching ^a   Kulp, Samuel K ^a   Teng, Che Ming ^b   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AR 42; CASEIN KINASE II; COP9 SIGNALOSOME; COP9 SIGNALOSOME SUBUNIT 5; DNA TOPOISOMERASE (ATP HYDROLYSING); ENTINOSTAT; F BOX PROTEIN; F BOX PROTEIN FBW7; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; SERINE; TOPOISOMERASE 2 ALPHA; TOPOISOMERASE 2 BETA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; HISTONE ACETYLATION; LIVER CARCINOGENESIS; LIVER CARCINOMA; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CASEIN KINASE II; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; F-BOX PROTEINS; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE INHIBITORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICE; MICE, NUDE; PEPTIDE HYDROLASES; PHENYLBUTYRATES; PHOSPHORYLATION; UBIQUITIN-PROTEIN LIGASES;

EID: 78751531789     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23964     Document Type: Article

References (41)

1. Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol 2006; 4: 252-261.
2. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-235.
3. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004; 127: S218-224.
4. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-8108.
5. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 2009; 44 Suppl 19: 136-141.
6. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. HEPATOLOGY 2007; 46: 1119-1130.
7. Xiao H, Mao Y, Desai SD, Zhou N, Ting CY, Hwang J, et al. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway. Proc Natl Acad Sci U S A 2003; 100: 3239-3244.
8. Zhang A, Lyu YL, Lin CP, Zhou N, Azarova AM, Wood LM, et al. A protease pathway for the repair of topoisomerase II-DNA covalent complexes. J Biol Chem 2006; 281: 35997-36003.
9. Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 2009; 124: 644-652.
10. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9: 338-350.
11. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007; 67: 8839-8846.
12. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A 2007; 104: 11014-11019.
13. Lu Q, Wang DS, Chen CS, Hu YD. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005; 48: 5530-5535.
14. Kulp SK, Chen CS, Wang DS, Chen CY. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006; 12: 5199-5206.
15. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63: 7291-7300.
16. Kurz EU, Wilson SE, Leader KB, Sampey BP, Allan WP, Yalowich JC, et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 2001; 1: 121-131.
17. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 2005; 11: 8467-8475.
18. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-381.
19. Ackerman P, Glover CV, Osheroff N. Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proc Natl Acad Sci U S A 1985; 82: 3164-3168.
20. Bojanowski K, Filhol O, Cochet C, Chambaz EM, Larsen AK. DNA topoisomerase II and casein kinase II associate in a molecular complex that is catalytically active. J Biol Chem 1993; 268: 22920-22926.
21. Yoshida K, Yamaguchi T, Shinagawa H, Taira N, Nakayama KI, Miki Y. Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage. Mol Cell Biol 2006; 26: 3414-3431.
22. Shapiro PS, Whalen AM, Tolwinski NS, Wilsbacher J, Froelich-Ammon SJ, Garcia M, et al. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol 1999; 19: 3551-3560.
23. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009; 66: 1858-1867.
24. Turner JG, Engel R, Derderian JA, Jove R, Sullivan DM. Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signals. J Cell Sci 2004; 117: 3061-3071.
25. Krehan A, Schmalzbauer R, Bocher O, Ackermann K, Wirkner U, Brouwers S, et al. Ets1 is a common element in directing transcription of the alpha and beta genes of human protein kinase CK2. Eur J Biochem 2001; 268: 3243-3252.
26. Wei N, Serino G, Deng XW. The COP9 signalosome: more than a protease. Trends Biochem Sci 2008; 33: 592-600.
27. Yun J, Tomida A, Andoh T, Tsuruo T. Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5. J Biol Chem 2004; 279: 31296-31303.
28. Uhle S, Medalia O, Waldron R, Dumdey R, Henklein P, Bech-Otschir D, et al. Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J 2003; 22: 1302-1312.
29. Harari-Steinberg O, Chamovitz DA. The COP9 signalosome: mediating between kinase signaling and protein degradation. Curr Protein Pept Sci 2004; 5: 185-189.
30. Cope GA, Deshaies RJ. Targeted silencing of Jab1/Csn5 in human cells downregulates SCF activity through reduction of F-box protein levels. BMC Biochem 2006; 7: 1.
31. Alchanati I, Teicher C, Cohen G, Shemesh V, Barr HM, Nakache P, et al. The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target. PLoS One 2009; 4: e8104.
32. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8: 83-93.
33. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003; 17: 349-368.
34. Kim HD, Tomida A, Ogiso Y, Tsuruo T. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. J Cell Physiol 1999; 180: 97-104.
35. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000; 60: 2429-2434.
36. Nakajima T, Morita K, Ohi N, Arai T, Nozaki N, Kikuchi A, et al. Degradation of topoisomerase IIalpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. J Biol Chem 1996; 271: 24842-24849.
37. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000; 26: 349-353.
38. Redwood C, Davies SL, Wells NJ, Fry AM, Hickson ID. Casein kinase II stabilizes the activity of human topoisomerase IIalpha in a phosphorylation-independent manner. J Biol Chem 1998; 273: 3635-3642.
39. Nayak MS, Yang JM, Hait WN. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 2007; 67: 5831-5839.
40. Lou Z, Minter-Dykhouse K, Chen J. BRCA1 participates in DNA decatenation. Nat Struct Mol Biol 2005; 12: 589-593.
41. Mao Y, Desai SD, Liu LF. SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem 2000; 275: 26066-26073.